If you've got $1,000 ready to invest, which won't be needed for bill or emergencies, the following five stocks would make for perfect buys for the fourth quarter. While I'm generally not a fan of chasing the coronavirus stocks after they've catapulted into the stratosphere, clinical-stage biotech stock Novavax (NASDAQ: NVAX) is the rare exception. The company's coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373, led to an 89.7% vaccine efficacy (VE) in a large-scale trial in the U.K. earlier this year, and it produced a nearly identical 90.4% VE in a large-scale trial in the U.S. and Mexico in June.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting